瑞舒伐他汀与辛伐他汀治疗老年冠心病伴高胆固醇血症患者血脂水平及生活质量的疗效观察

Therapeutic effects of rosuvastatin and simvastatin on blood lipid levels and quality of life of elderly patients with coronary heart disease and hypercholesterolemia

目的探讨瑞舒伐他汀与辛伐他汀治疗老年冠心病伴高胆固醇血症患者的血脂水平及生活质量的对比疗效。方法选择我院2017年8月~2018年8月收治的89例患者随机分为观察组(n=45)和对照组(n=44)。两组均进行常规基础治疗,对照组采用辛伐他汀片治疗,观察组采用瑞舒伐他汀钙片治疗。观察比较两组治疗前后的血脂水平(TC、TG、HDL-C、LDL-C)、SF-36评分及不良反应发生情况。结果治疗后,两组TC、LDL-C水平较治疗前下降,差异有统计学意义(P<0.05)。而且,观察组TC、LDL-C水平较对照组明显下降,差异有统计学意义(P<0.05)。治疗后,观察组SF-36评分中GH、VT、RE较治疗前显著升高,且显著高于对照组(P<0.01),而BP、PF、RP、SF、MH则无显著变化(P>0.05)。观察组治疗后SF-36评分总分[(93.83±6.55)分]与治疗前[(90.68±8.26)分]比较显著升高(t=-1.996,P=0.049),而且与对照组[(89.35±10.74)分]相比亦显著升高(t=2.369,P=0.021)。观察组不良反应为8.88%,与对照组9.09%比较,无显著变化(χ2=0.001,P=0.973)。结论瑞舒伐他汀治疗老年冠心病伴高胆固醇血症临床疗效显著,可有效改善患者血脂水平,降低低密度脂蛋白,提高患者生活质量,药物安全性高,值得推广应用。

Objective To investigate the therapeutic effects of rosuvastatin and simvastatin on the blood lipid levels and quality of life of elderly patients with coronary heart disease and hypercholesterolemia.Methods Eighty-nine patients admitted to our hospital from August 2017 to August 2018 were randomly divided into the observation group(n=45)and the control group(n=44).Conventional basic treatment was performed in both groups,on the basis of which the control group was treated with simvastatin tablets and the observation group was treated with rosuvastatin calcium tablets.The blood lipid levels(TC,TG,HDL-C and LDL-C),SF-36 scores and adverse reactions of the two groups were observed before and after treatment.Results After treatment,the levels of TC and LDL-C in both groups were lower than those before treatment,with statistically significant differences(P<0.05),and the levels of TC and LDL-C in the observation group were significantly lower than those in the control group,with statistically significant differences(P<0.05).After treatment,GH,VT,and RE of the SF-36 score in the observation group were significantly higher than those before treatment,and were significantly higher than those in the control group(P<0.01),while no significant changes were observed in BP,PF,RP,SF and MH(P>0.05).After treatment,the total score of SF-36 in the observation group was(93.83±6.55),which was significantly higher than the(90.68±8.26)before treatment(t=-1.996,P=0.049),and was also significantly higher than the(89.35±10.74)of the control group(t=2.369,P=0.021).The incidence of adverse reactions in the observation group was 8.88%,which was not significantly different from the 9.09%in the control group(χ2=0.001,P=0.973).Conclusion Rosuvastatin shows remarkable clinical efficacy in the treatment of elderly patients with coronary heart disease and hypercholesterolemia.It can effectively improve the blood lipid levels,reduce low-density lipoprotein and improve the quality of life of patients,and has high drug safety,thereby worthy of promotion and application.